Developmental and transplacental genotoxicology: Fluconazole

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 657, Issue 1, 2008, Pages 43-47

  Fucic, Aleksandra ^a   Markovic, Darko ^b   Herceg, Zdenko ^c   Gamulin, Marija ^d   Katic, Jelena ^a   Stojkovic, Ranko ^e   Ferencic, Zeljko ^b   Mildner, Boris ^b   Jazbec, Ana Marija ^f   Dobranic, Tomislav ^g  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^b GLAXOSMITHKLINE   (United Kingdom)

^c International Agency for Research on Caner   (France)

^d KBC Zagreb   (Croatia)

^e RUDER BO KOVI INSTITUTE   (Croatia)

^f UNIVERSITY OF ZAGREB   (Croatia)

^g UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Development; Fluconazole; Micronucleus assay; Systems biology; Transplacental genotoxicity

Indexed keywords

FLUCONAZOLE; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOGENETICS; DEVELOPMENTAL BIOLOGY; EXPERIMENTAL MOUSE; FEMALE; GENETIC DAMAGE; GENOTOXICITY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MICRONUCLEUS; MOUSE; NEWBORN; NONHUMAN; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; PUBERTY; RADIOCHEMISTRY; SINGLE DRUG DOSE; TUMOR PROMOTION;

AGING; ANIMALS; FEMALE; FLUCONAZOLE; MATERNAL-FETAL EXCHANGE; MICE; MICE, INBRED BALB C; MICRONUCLEUS TESTS; MUTAGENS; PREGNANCY;

ANIMALIA; MUS;

EID: 56349144612     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2008.08.008     Document Type: Article

References (58)

1. McNally R.J.Q., Eden T.O.B., Alexander F.E., Kelsey A.M., and Birch J.M. Is there a common aetiology for certain childhood malignancies? Results of cross-space-time clustering analyses. Eur. J. Cancer 41 (2005) 2911-2916
2. Myllynen P., Pasanen M., and Vahakangas K. The fate and effects of xenobiotics in human placenta. Expert Opin. Drug Metab. Toxicol. 3 (2007) 331-346
3. Hsieh M.H., Grantham E.C., Liu B., Macapaqual R., Willingham E., and Baskin L.S. In utero exposure to benzophenone-2 causes hypospadias through an estrogen receptor dependent mechanism. J. Urol. 178 (2007) 1637-1642
4. Xie Y., Liu J., Benbrahim-Tallaa L., Ward J.M., Logsdon D., Diwan B.A., and Waalkes M.P. Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to hepatocarcinogenic dose of inorganic arsenic. Toxicology 236 (2007) 7-15
5. Cimino M.C. Comparative overview of current international strategies and guidelines for genetic toxicology testing for regulatory purposes. Environ. Mol. Mutagen. 47 (2006) 362-390
6. Matthews E.J., Kruhla N.L., Cimino M.C., Benz R.D., and Contrera J.F. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data. I. Identification of carcinogens using surrogate endpoints. Regul. Toxicol. Pharmacol. 44 (2006) 83-96
7. Jick S.S. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 19 (1999) 221-222
8. Sorensen H.T., Nielsen G.L., Olesen C., Larsen H., Steffensen F.H., Schonheyder H.C., Olsen J., and Czeizel A.E. Risk of malformations and other outsomes in children exposed to fluconazole in utero. Br. J. Clin. Pharmacol. 48 (1999) 234-238
9. Francois I.E.J.A., Cammue B.P.A., Borgers M., Ausma J., Dispersyn G.D., and Thevissen K. Azoles: Mode of antifungal action and resistamce dvelopment. Effect of miconazole on endogenous reactive oxygen species production in Candida albicans. Anti-infective Agents Med. Chem. 5 (2006) 3-13
10. Tiboni G.M. Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res. Commun. Chem. Pathol. Pharmacol. 79 (1993) 381-384
11. Tiboni G.M., Iammarrone E., Giampietro F., Lamonaca D., Bellati U., and Di Ilio C. Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin. Teratology 59 (1999) 81-87
12. Moudgal V.V., and Sobel J.D. Antifugal drugs in pregnancy: a review. Expert Opin. Drug Saf. 2 (2003) 475-483
13. Menegola E., Broccia M.L., Di Renzo F., Massa V., and Giavini E. Relationship between hindbrain segmentation, neural crest cell migration and branchial arch abnormalities in rat embryos exposed to fluconazole and retinoic acid in vitro. Reprod. Toxicol. 18 (2004) 121-130
14. Lee B.E., Feinberg M., Abraham J.J., and Murthy A.R. Congenital malformations in an infant born to a woman treated to flucanozole. Pediatr. Infect. Dis. 11 (1992) 1062-1064
15. Pursley T.J., Blomquist I.K., Abraham J., Andersen H.F., and Bartley J.A. Flucanozole-induced congenital anomalities in three infants. Clin. Infect. Dis. 22 (1996) 336-340
16. Aleck K.A., and Bartley D.L. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am. J. Med. Genet. 72 (1997) 253-256
17. Reardon G.L. Evidence for disgenic inheritance in some cases of Antley-Bixler syndrome. J. Med. Genet. 37 (2000) 26-32
18. Lopez-Rangel E., and Van Allen M.I. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res. A 73 (2005) 919-923
19. Menegola E., Broccia M.L., Di Renzo F., and Giavini E. Pathogenic pathways in fluconazole-induced branchial arch malformations. Birth Res. A 67 (2003) 116-124
20. Menegola E., Broccia M.L., Di Renzo F., and Giavini E. Postulated pathogenic pathway in triazole fungicide induced dysmorphogenic effects. Reprod. Toxicol. 2 (2006) 186-195
21. Hayashi M., Morita T., Sofuni T., and Ishidate M. The micronucleus assay with mouse peripheral blood reticilocyte using acridine orange-coated slides. Mutat. Res. 245 (1990) 245-249
22. Graybill J.R., Najvar L.K., Holmberg J.D., and Luther M.F. Fluconazole D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob. Agents Chemother. 39 (1995) 924-929
23. Kamberi P., Sobel R.A., Clemons K.V., Waldvogel A., Striebel J.M., Williams P.L., and Stevens D.A. Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. Antimicrob. Agents Chemother. 51 (2007) 998-1003
24. T. Morita, N. Asano, T. Awogi, Yu F. Sasaki, S. Sato, H. Shimada, S. Sutou, T. Suzuki, A. Wakata, T. Sofuni, M. Hayashi. Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (Groups 1, 2A and 2B). The summary report of the 6th collaborative study by CSGMT/JEMS MMS, Mutat. Res. 389 (1997) 3-114.
25. Fein A., Bennun O., Wenger N., Torchinsky A., and Toder V. The effect of cyclophosphamide on rat blastocysts in vitro and their subsequent development following transfer to pseudopregnant rats. Isr. J. Med. 32 (1996) 129-134
26. Heringova L., Jelinek R., and Dostal M. Cell cycle alterations underlie cyclophosphamide-induced teratogenesis in the chick embryo. Birth Defects Res. 67 (2003) 438-443
27. Humphrey M.J., Jevons S., and Tarbit M.H. Pharmacokinetic evaluation of a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28 (1985) 648-653
28. Goa K.L., and Barradell L.B. Fluconazole: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50 (1995) 658-690
29. Serron S.C., Dwivedi N., and Backes W.L. Ethylbenzene induces microsomal oxygen free radical generation: antibody-directed characteriazation of the responsible cytochrome P450 enzymes. Toxicol. Appl. Pharmacol. 164 (2000) 305-311
30. Vanden-Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr. Top. Med. Mycol. 1 (1985) 313-351
31. Zarn J.A., Brüschweiler B.J., and Sclatter J.R. Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14α-demethylase and aromatase. Environ. Health Perspect. 111 (2003) 255-261
32. Režen T., Debeljak N., Kordiš D., and Rozman D. New aspects on lanosterol 14α-demethylase and cytochrome P450 evolution: lanosterol/cycloartenol diversification and lateral transfer. J. Mol. Evol. 59 (2004) 51-58
33. Trösken E.R., Straube E., Lutz W.K., Völkel W., and Patten C. Quantitation of lanosterol and its major metabolite FF-MAS in an inhibition assay of CYP51 by azoles with atmospheric pressure photoionization based LC-MS/MS. J. Am. Soc. Mass Spectrom. 15 (2004) 1216-1221
34. Trösken E.R., Scholz K., Lutz R.W., Völkel W., Zarn J.A., and Lutz W.K. Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azole used in agriculture and as drugs in humans. Endocr. Res. 30 (2004) 387-394
35. Trösken E.R., Fischer K., Völkel W., and Lutz W.K. Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation. Toxicology 219 (2006) 33-40
36. Prowell T.M., Facker M.J., Argani P., Khouri N.F., Blackford A.L., Shahverdi K., Wolff A.C., Davidson N.E., Sukumar S., and Stearns V. Effect of treatment with adjuvant anastrozole on cumulative gene methylation in the contralateral breast of women at increased risk for a second breast cancer. ASCO Breast Cancer Symp. Book Abstr. (2007) 1
37. Reik W., Dean W., and Walter J. Epigenetic reprogramming in mammalian development. Science 293 (2001) 1089-1093
38. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22 (2007) 91-103
39. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
40. Feinberg A.P., and Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 4 (2004) 143-153
41. Jones P.A. DNA methylation and cancer. Oncogene 21 (2002) 5358-5360
42. Lobstein R., Lalkin A., and Koren G. Pharmakokinetic changes during pregnancy and their clinical relevance. Clin. Pharmakokinet. 33 (1997) 328-343
43. Mendenhall H.W. Serum protein concentrations in pregnancy. I. Concentrations in maternal serum. Am. J. Obstet. Gynecol. 106 (1970) 388-399
44. Fredriksen M.C. Physiological changes in pregnancy and their effect on drug disposition. Semin. Perinatol. 25 (2001) 120-123
45. Bologa M., Tang B., and Klein J. Pregnancy-induced changes in drug metabolism in epileptic women. J. Pharmacol. Exp. Ther. 257 (1991) 735-740
46. Nahata M.C., and Brady M.T. Pharmacokinetics of fluconazole after oral administration in very low birth weight infants during the first two weeks of life. Eur. J. Clin. Pharmacol. 48 (1995) 291-293
47. Lee J.W., Seibel N.L., Amantea M., Whitcomb P., Pizzo P.A., and Walsh T.J. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr. 120 (1992) 987-993
48. Gow P.J., Ghabrial H., Smallwood R.A., Morgan D.J., and Ching M.S. Neonatal hepatic drug elimination. Pharmacol. Toxicol. 88 (2001) 3-15
49. Wells P.G., Bhuller Y., Chen C.S., Jeng W., Kasapinovic S., Kennedy J.C., Kim P.M., Laposa R.R., McCallum G.P., Nicol C.J., Parman T., Wiley M.J., and Wong A.W. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol. Appl. Pharmacol. 207 (2005) 354-366
50. Ginsberg G., Hattis D., Sonawane B., Russ A., Banati P., Kozlak M., Smolenski S., and Goble R. Evaluation of child/adult pharmacokinetic difference from a database derived from the therapeutic drug literature. Toxicol. Sci. 66 (2002) 185-200
51. Beuret C.J., Zirulnik F., and Gimenez M.S. Effect of the herbicide glyphosate on liver lipoperoxidation in pregnant rats and their fetuses. Reprod Toxicol. 19 (2005) 501-504
52. Hakota J., Raunio H., Purkunen R., Saarikoski S., Vahakangas K., Pelkonen O., Edwards R.J., Boobis A.R., and Pasanen M. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol. Neonate 80 (2001) 193-201
53. Dubuisson J.G., Murph W.S., Griffin S.R., and Gaubatz J.W. Cytosolic enzymes from rat tissues that active the cooked meat mutagen metabolite N-hydroxyamino-1-methyl-6-phenylimidazo (4,5)pyridine (N-OH-PhIP). J. Nutr. Biochem. 12 (2001) 518-528
54. Lundqvist G., and Morgenstern R. Ontogenesis of rat liver microsomal glutathione transferase. Biochem. Pharmacol. 50 (1995) 421-423
55. Barbasi A.L., and Oltvai Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 5 (2004) 101-113
56. Goh K.I., Cusik M.E., Valle D., Childs B., Vidal M., and Barbasi A.L. The human disease network. PNAS 104 (2007) 8685-8690
57. Davidson E.H., Rast J.P., Oliveri P., Ransick A., Calestani C., Yuh C.H., Minokawa T., Amore G., Hinman V., Arenas-Mena C., Otim O., Brown C.T., Livi C.B., Lee P.Y., Revilla R., Rust A.G., Pan Z.J., Schilstra M.J., Clarke P.J.C., Arnone M.I., Rowen L., Cameron R.A., McClay D.R., Hood L., and Bolouri H. A genomic regulatory network for development. Science 295 (2002) 1669-1678
58. Hu Z., Mellor J., Wu J., Kanehisa M., Stuart J.M., and DeLisi C. Towards zoomable multidimensional maps of the cell. Nat. Biotechnol. 25 (2007) 547-554